Biocytogen’s Post

ICYMI: Lung cancer is the leading cause of #cancer deaths globally, with #NSCLC constituting 85% of cases. Despite treatment advances, the five-year NSCLC survival rate remains low, necessitating better diagnostic tools and targeted therapies. Today’s blog outlines new #bioinformatics research that used #scRNAseq and #spatialtranscriptomics to identify immune cells in NSCLC, finding cancer-associated macrophage-like cells (#CAMLs) linked to poorer survival outcomes: https://lnkd.in/evyy594t

What is hormone therapy for prostate cancer and how does it work? Treatment for prostate cancer depends on a few factors, including the stage and grade of the cancer, as well as your overall health, age and your own preferences.¹ One type of prostate cancer treatment is known as hormone therapy or androgen deprivation therapy (ADT).  To learn more about hormone therapy for prostate cancer, please click though to our blog post. https://lnkd.in/gpMYqzyi 1. Cancer Council. Understanding Prostate Cancer. A guide for people with cancer, their families and friends. Available at: https://lnkd.in/gYAccnae (accessed May 2024). #designingbettercare #prostatecancer #prostatecancerawareness #cancercare

September is Prostate Cancer Awareness Month 💙 Prostate Cancer is one of the most common major cancers among men. According to the National Cancer Institute and the American Cancer Society, there will be an estimated 299,010 new prostate cancer cases in 2024. The most common way to check for prostate cancer is to have a routine prostate-specific antigen (PSA) blood test and a prostate exam. The recommended age for men to begin early screening for prostate cancer is as early as age 50. #ProstateCancerAwareness #ProstateHealth #CancerAwareness #MensHealth #PSATest #EarlyDetection #CancerPrevention #SeptemberAwareness #HealthScreening #ProstateCancerFacts #KnowYourHealth #RoutineScreening #MensHealthMatters #HudsonHillHealthcare #SkilledNursingFacility #Rehabilitation

CEACAM5, also known as CEA, is a membrane glycoprotein found in the intestines, pancreas, bile ducts, and liver, involved in cell adhesion, signaling, and immune regulation. Highly expressed in many malignant tumors, CEACAM5 is a key biomarker for cancer diagnosis and monitoring. While its therapeutic role is still being studied, it is widely used in cancer diagnosis and treatment. Learn more about CEACAM5 reagents here: https://bit.ly/3zIu9i1

When it comes to cancer-fighting immunotherapies, T cells have largely occupied the spotlight. However, recent research has started to uncover the complex role of tumor-infiltrating B lymphocytes (TIL-Bs) in cancer. Certain subtypes have been shown to enhance antitumor immune activity, while others promote inflammation and suppress the immune response. Studying glycosylation may be the key to understanding how B cells develop, differentiate, and interact with their targets. Check out our blog to learn more about how glycans influence adaptive immunity: https://bit.ly/4c0cCQ3 #Glycobiology #Immunotherapy #AdaptiveImmunity

In 1144 esophageal cancer patients, circulating tumor DNA (ctDNA) has been quantitatively linked to poorer outcomes, with hazard ratios of 3.87 for overall survival and 4.28 for progression-free survival. The sensitivity of ctDNA in neoadjuvant therapy was determined to be 13.1%, with specific mutations like TP53 NOTCH1, CDKN2A amplification present. This evidence suggests ctDNA's utility in personalized cancer management, albeit with the need for further large-scale studies to bolster these findings. #EsophagealCancer #ctDNA #SurvivalRates #PersonalizedMedicine #ClinicalTrials

🗞 Nature Communications recently published an article on the MIND-DC phase III trial, which investigated the influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma   💭 Exeliom co-founder and chief medical officer Harry Sokol shares his thoughts: "The gut microbiota has a major impact on immune response. In the cancer context, and particularly for melanoma, the gut microbiota plays a role in modulating the response to immunotherapies, including immune checkpoint inhibitors. In this study, the authors showed that different microbes were associated with prognosis, with the health-related Faecalibacterium prausnitzii standing out as the main beneficial taxon for no recurrence at 2 years."   Read the full article 👇 https://lnkd.in/eChM4HgT Nature Portfolio #microbiota #research #cancer #melanoma #immunotherapy

September is Prostate Cancer Awareness Month 💙 Prostate Cancer is one of the most common major cancers among men. According to the National Cancer Institute and the American Cancer Society, there will be an estimated 299,010 new prostate cancer cases in 2024. The most common way to check for prostate cancer is to have a routine prostate-specific antigen (PSA) blood test and a prostate exam. The recommended age for men to begin early screening for prostate cancer is as early as age 50. #ProstateCancerAwareness #ProstateHealth #CancerAwareness #MensHealth #PSATest #EarlyDetection #CancerPrevention #SeptemberAwareness #HealthScreening #ProstateCancerFacts #KnowYourHealth #RoutineScreening #MensHealthMatters #YonkersHealthcare #SkilledNursingFacility #Rehabilitation

Comparing Side Effects After Prostate Cancer Treatment Although prostate cancer is the most common cancer in men worldwide, it has a relatively good prognosis. Most men with prostate cancer will still be alive 15 years after diagnosis. Currently, men with prostate cancer that has not spread outside the gland have several treatment options. Because most men with prostate cancer are expected to live a long time, it is important to weigh the long-term side effects of different treatments. Side effects may include bladder and bowel problems and difficulty with sexual functioning. Find out more by visiting the link: https://bit.ly/4b6GOZU #nih #clincoord #effectsafterprostatecancer #prostatecancersearch

From the AMMG E-Journal, Blood Test for 50 Types of Cancer Could Speed Up Diagnosis, Study Suggests: https://bit.ly/3x1lMMQ. "A blood test for more than 50 forms of cancer could help speed up diagnosis and fast-track patients for treatment, a study suggests. NHS trial results of the liquid biopsy, published at the world’s largest cancer conference in the US, suggest the Galleri blood test has the potential to spot and rule out cancer in people with symptoms. The test detects tiny fragments of tumor DNA in the bloodstream. It alerts doctors as to whether a cancer signal has been detected, and predicts where in the body that signal may have originated." #CancerBloodTest #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences